This also suggested that during the chemotherapy cycle, continuous use of the same G-CSF type can better ensure the recovery of WBC counts and ANCs after chemotherapy and reduce the duration of leukopenia and neutropenia. This evidence concerns the gene CSF3 and neutropenia.